Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,851 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The pathogenesis of dermatomyositis.
Thompson C, Piguet V, Choy E. Thompson C, et al. Br J Dermatol. 2018 Dec;179(6):1256-1262. doi: 10.1111/bjd.15607. Epub 2017 May 24. Br J Dermatol. 2018. PMID: 28542733 Review.
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.
Humby F, Durez P, Buch MH, Lewis MJ, Rizvi H, Rivellese F, Nerviani A, Giorli G, Mahto A, Montecucco C, Lauwerys B, Ng N, Ho P, Bombardieri M, Romão VC, Verschueren P, Kelly S, Sainaghi PP, Gendi N, Dasgupta B, Cauli A, Reynolds P, Cañete JD, Moots R, Taylor PC, Edwards CJ, Isaacs J, Sasieni P, Choy E, Pitzalis C; R4RA collaborative group. Humby F, et al. Lancet. 2021 Jan 23;397(10271):305-317. doi: 10.1016/S0140-6736(20)32341-2. Lancet. 2021. PMID: 33485455 Free PMC article. Clinical Trial.
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial.
Rivellese F, Surace AEA, Goldmann K, Sciacca E, Çubuk C, Giorli G, John CR, Nerviani A, Fossati-Jimack L, Thorborn G, Ahmed M, Prediletto E, Church SE, Hudson BM, Warren SE, McKeigue PM, Humby F, Bombardieri M, Barnes MR, Lewis MJ, Pitzalis C; R4RA collaborative group. Rivellese F, et al. Nat Med. 2022 Jun;28(6):1256-1268. doi: 10.1038/s41591-022-01789-0. Epub 2022 May 19. Nat Med. 2022. PMID: 35589854 Free PMC article. Clinical Trial.
A Clinical Practice-Based Comparison of Conventional and Individualized Dosing Strategies for Therapeutic Enoxaparin.
Damiani A, De Menezes Caceres V, Roberts G, Coddo J, Scarfo N, Willliams DB, Tharmathurai V, Tadros R, Fitzgerald S, O'Connell A, Kaur Sandhu A, Vanlint A, Mangoni AA, Hofmann D, Bony H, Faunt J, Boey JP, Farinola N, Wells R, Hedger S, Hewage U, Sharma Y, Jabbar Z, Thomas J, Flabouris K, Gilbert T, Thompson C, Russell P. Damiani A, et al. Among authors: thompson c. Pharmacol Res Perspect. 2025 Feb;13(1):e70039. doi: 10.1002/prp2.70039. Pharmacol Res Perspect. 2025. PMID: 39853909
Acceptability and preliminary outcomes of the Enhanced Assess, Acknowledge, and Act Sexual Assault Resistance Education Program for women who use alcohol and cannabis (EAAA+): Findings from an open pilot trial.
Leone RM, Franklin-Kidd M, Gayer E, Brown J, Patel R, Thompson C, Mullican KN, Salazar LF, Neighbors C, Gilmore AK, Gray KM, Senn C. Leone RM, et al. Among authors: thompson c. J Stud Alcohol Drugs. 2025 Jan 22. doi: 10.15288/jsad.24-00183. Online ahead of print. J Stud Alcohol Drugs. 2025. PMID: 39841440
7,851 results